SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae
Corporation (NYSE: NVTA) today announced the exercise in full of
the underwriters' option to purchase an additional 1,350,000 shares
of its common stock at the public offering price of $19.00 per share, in connection with Invitae's
recently announced underwritten public offering of 9,000,000 shares
of its common stock. As a result of the underwriters' option
exercise, the aggregate gross proceeds to Invitae from the
offering, before deducting the underwriting discounts and
commissions and other offering expenses, are expected to be
approximately $196.7 million.
The offering is expected to close on or about March 8, 2019, subject to the satisfaction of
customary closing conditions.
J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB
Leerink LLC are acting as the book-running managers for the
offering.
An automatic shelf registration statement relating to the shares
was filed with the Securities and Exchange Commission and became
effective on March 4, 2019. A copy of
the final prospectus supplement and accompanying prospectus
relating to the offering may be obtained from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or from Cowen and Company, LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (631) 274-2806; or from SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a leading genetics company
whose mission is to bring comprehensive genetic information into
mainstream medicine to improve healthcare for billions of people.
Invitae's goal is to aggregate the world's genetic tests into a
single service with higher quality, faster turnaround time, and
lower prices.
Forward-Looking Statements
This press release contains forward-looking statements within
the Private Securities Litigation Reform Act of 1995, including
statements relating to Invitae's expectations regarding the
completion, timing and size of the public offering. Actual results
or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause
such a difference include risks and uncertainties related to
completion of the public offering on the anticipated terms or at
all, market conditions and the satisfaction of customary closing
conditions related to the public offering. More information about
the risks and uncertainties faced by Invitae is contained in the
section captioned "Risk factors" in the preliminary prospectus
supplement related to the public offering filed with the Securities
and Exchange Commission. Invitae disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
Laura D'Angelo
ir@invitae.com
(628) 213-3369
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invitae-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-of-common-stock-300808200.html
SOURCE Invitae Corporation